Alexion Says Soliris Study Data Supports Long-Term Efficacy and Safety
March 08 2019 - 10:37AM
Dow Jones News
By Michael Dabaie
Alexion Pharmaceuticals Inc. (ALXN) said Friday data from an
interim analysis of a study of Soliris indicate improvements during
the initial six-month trial duration were sustained over a three
year period.
The Phase 3 open-label extension study evaluated the long-term
efficacy and safety of Soliris in adult with generalized myasthenia
gravis in muscle and nerve.
Additionally, patients who had previously been treated with
placebo in the study showed rapid and significant improvement upon
starting treatment with Soliris in the open-label extension, the
company said.
Shares were down 1.5% to $126.25 Friday morning.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
March 08, 2019 10:22 ET (15:22 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Apr 2023 to Apr 2024
